MASSDEVICE ON CALL — A pair of important medical device industry legislations were momentarily combined when Sen. Orrin Hatch (R-Utah) announced plans to include language repealing the 2.3% medical device tax in a bill reauthorizing the user fees device and drug makers pay for FDA review.
The effort was short-lived. On Monday Sen. Dan Coates, a co-sponsor of the Hatch amendment, conceded that Hatch planned to find "another vehicle" for his tax repeal efforts so as to avoid stalling the FDA user fee agreements.